In this episode of Behind the Bell, Genmab President & CEO Jan van de Winkel reflects on 25 years of Genmab. Genmab is an international biotechnology company creating innovative and differentiated antibody therapeutics to improve the lives of patients.
Watch more of Behind the Bell on Nasdaq.com: https://www.nasdaq.com/news-and-insights/behind-the-bell
source